Novavax
(NASDAQ) NVAX
Novavax Financials at a Glance
Market Cap
$1.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$596.34M
Net Income (TTM)
-$87.84M
EPS (TTM)
-$0.60
P/E Ratio
-15.83
Dividend
$0.00
Beta (Volatility)
1.80 (High)
Dividend
$0.00
Beta (Volatility)
1.80 (High)
Price
$9.35
Volume
1,314,306.149
Open
$9.28
Price
$9.35
Volume
1,314,306.149
Open
$9.28
Previous Close
$9.46
Daily Range
$9.15 - $9.54
52-Week Range
$6.20 - $11.97
Estimated Earnings Date
Aug 5, 2026
Dividend
$0.00
Beta (Volatility)
1.80 (High)
Price
$9.35
Volume
1,314,306.149
Open
$9.28
Previous Close
$9.46
Daily Range
$9.15 - $9.54
52-Week Range
$6.20 - $11.97
Estimated Earnings Date
Aug 5, 2026
NVAX News
How Bad Is This News for Novavax?
NVAX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Novavax
Industry
Biotechnology
Sector
Health CareEmployees
749
CEO
John C.s Jacobs, MBA
Website
www.novavax.comHeadquarters
Gaithersburg, MD 20878, US
NVAX Financials
Key Financial Metrics (TTM)
Gross Margin
84.64%
Operating Margin
-11.19%
Net Income Margin
-14.73%
Return on Equity
89.73%
Return on Capital
465.29%
Return on Assets
-8.42%
Earnings Yield
-6.32%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
164.44M
Volume
1.31M
Avg. Volume
4.79M
Financials (TTM)
Gross Profit
$504.72M
Operating Income
-$66.76M
EBITDA
-$42.13M
Operating Cash Flow
-$91.56M
Capital Expenditure
-$5.61M
Free Cash Flow
-$97.17M
Cash & ST Invst.
$790.33M
Total Debt
$295.06M
Novavax Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$139.51M
-79.1%
Gross Profit
$108.82M
-83.3%
Gross Margin
78.00%
N/A
Market Cap
$1.56BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$2.08M
N/A
Employees
749
N/A
Net Income
-$9.49M
-101.8%
EBITDA
-$543.00K
-100.1%
Quarterly Fundamentals
Total Cash
$790.33M
+8.0%
Total Debt
$295.06M
+29.0%
Accounts Receivable
$23.31M
-47.6%
Inventory
$11.46M
+11.6%
Long Term Debt
$292.95M
+31.3%
Short Term Debt
$2.11M
-61.4%
Return on Assets
-8.42%
N/A
Return on Invested Capital
-9.53%
N/A
Free Cash Flow
-$33.69M
+82.0%
Operating Cash Flow
-$32.42M
+82.5%